# Complement Therapeutics



## Pages


- [Investors](https://www.complementtx.com/investors)

- [Home](https://www.complementtx.com/)

- [News](https://www.complementtx.com/blog)

- [Pipeline](https://www.complementtx.com/copy-of-home)

- [Overview](https://www.complementtx.com/science)

- [For Patients](https://www.complementtx.com/patient-information)

- [Careers](https://www.complementtx.com/careers)

- [Presentation](https://www.complementtx.com/investor-presentation)

- [Board of Directors](https://www.complementtx.com/board-of-directors)

- [Our Research](https://www.complementtx.com/our-research)

- [Technology](https://www.complementtx.com/technology)

- [Platform](https://www.complementtx.com/platform)

- [Meet the Team](https://www.complementtx.com/about-us)

- [Clinical Trials](https://www.complementtx.com/clinical-trials)


## Blog Posts


- [Complement Therapeutics Announces Completion of Cohort 2 Dosing and Favourable IDMC Recommendation to Proceed to High Dose and Expansion Cohorts in the Phase I/II Opti-GAIN Study](https://www.complementtx.com/complement-therapeutics-announces-completion-of-cohort-2-dosing-and-favourable-idmc-recommendation-to-proceed-to-high-dose-and-expansion-cohorts-in-the-phase-i-ii-opti-gain-study)

- [Complement Therapeutics Announces Completion of Cohort 1 Dosing and Favourable Independent Data Monitoring Committee Recommendation in the Phase I/II Opti-GAIN Study for GA Secondary to AMD](https://www.complementtx.com/complement-therapeutics-announces-completion-of-cohort-1-dosing-and-favourable-independent-data-monitoring-committee-recommendation-in-the-phase-i-ii-opti-gain-study-for-geographic-atrophy-secondary-t)

- [Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD](https://www.complementtx.com/complement-therapeutics-announces-first-patient-dosed-with-ctx001-in-the-phase-i-ii-opti-gain-study-for-geographic-atrophy-secondary-to-amd)

- [Complement Therapeutics Receives UK CTA Approval to Advance CTx001 into Opti-GAIN Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD](https://www.complementtx.com/complement-therapeutics-receives-uk-cta-approval-to-advance-ctx001-into-opti-gain-phase-i-ii-clinical-trial-in-geographic-atrophy-secondary-to-amd)

- [Touchlight, Cell and Gene Therapy Catapult and Complement Therapeutics to develop innovative manufacturing process for gene therapies](https://www.complementtx.com/touchlight-cell-and-gene-therapy-catapult-and-complement-therapeutics-to-develop-innovative-manufacturing-process-for-gene-therapies)

- [Complement Therapeutics Appoints Dr Muhammad Ali Memon FRCOphth, as Chief Medical Officer](https://www.complementtx.com/complement-therapeutics-appoints-dr-muhammad-ali-memon-frcophth-as-chief-medical-officer)

- [Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD](https://www.complementtx.com/complement therapeutics receives fda ind clearance to advance ctx001 into opti-gain, a phase i/ii clinical trial in geographic atrophy secondary to amd)

- [Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD](https://www.complementtx.com/complement-therapeutics-receives-fda-ind-clearance-to-advance-ctx001-into-opti-gain-a-phase-i-ii-clinical-trial-in-geographic-atrophy-secondary-to-amd)

- [Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD](https://www.complementtx.com/complement-therapeutics-announces-fda-fast-track-designation-for-ctx001-for-the-treatment-of-geographic-atrophy-secondary-to-amd)

- [Complement Therapeutics Announces the Establishment of Medical Advisory Board ](https://www.complementtx.com/complement-therapeutics-announces-the-establishment-of-medical-advisory-board)

- [Complement Therapeutics Announces the Establishment of Medical Advisory Board ](https://www.complementtx.com/complement-therapeutics-announces-the-establishment-of-medical-advisory-boarda6195022)

- [Complement Therapeutics Appoints Dr. Matthias Hebben, as Chief Technology Officer](https://www.complementtx.com/complement-therapeutics-appoints-dr-matthias-hebben-as-chief-technology-officer)

- [Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with Geographic Atrophy](https://www.complementtx.com/complement-therapeutics-enrols-first-us-participant-in-the-non-interventional-i-gain-study-of-people-diagnosed-with-geographic-atrophy)